Metal complexes in medicine with a focus on enzyme inhibition

Current Opinion in Chemical Biology

Volumn 14, Issue 2, 2010, Pages 255-261

  Che, Chi Ming ^a   Siu, Fung Ming ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CISPLATIN; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GOLD DERIVATIVE; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; METAL COMPLEX; P21 ACTIVATED KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 1; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; RUTHENIUM DERIVATIVE; TELOMERASE; TELOMERASE INHIBITOR;

COMPLEX FORMATION; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; MOLECULAR DOCKING; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 77949889854     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2009.11.015     Document Type: Review

References (29)

1. Sun R.W.Y., Ma D.L., Wong E.L.M., and Che C.M. Some uses of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans (2007) 4884-4892. This review focuses the uses of metal-based drugs as anticancer and anti-HIV agents.
2. Chen D., Milacic V., Frezza M., and Dou Q.P. Metal complexes, their cellular targets and potential for cancer therapy. Curr Pharm Des 15 (2009) 777-791. This review focuses on the development of non-platinum metal complexes as anticancer drugs.
3. Bruijnincx P.C.A., and Sadler P.J. New trends for metal complexes with anticancer activity. Curr Opin Chem Biol 12 (2008) 197-206. The use of metal as scaffold rather than reactive center and the departure from cisplatin paradigm of activity toward a more targeted, cancer cell-specific approach were discussed in this review.
4. Van Rijt S.H., and Sadler P.J. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov Today 14 (2009) 1089-1097
5. Angelucci F., Sayed A.A., Williams D.L., Boumis G., Brunori M., Dimastrogiovanni D., Miele A.E., Pauly F., and Bellelli A. Inhibition of Schistosoma mansoni thioredoxin glutathione reductase by auranofin: structural and kinetic aspects. J Biol Chem 284 (2009) 28977-28985
6. Mirabelli C.K., Johnson R.K., Sung C.M., Faucette L., Muirhead K., and Crooke S.T. Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res 45 (1985) 32-39
7. Ott I., Qian X., Xu Y., Vlecken D.H., Marques I.J., Kubutat D., Will J., Sheldrick W.S., Jesse P., Prokop A., et al. A gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor. J Med Chem 52 (2009) 763-770
8. Milacic V., Chen D., Ronconi L., Landis-Piwowar K.R., Fregona D., and Dou Q.P. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res 66 (2006) 10478-10486. An in vivo study revealed that gold(III) dithiocarbamate compound is a promising anticancer agent that inhibits the activity of 20S proteasome and 26S proteasome.
9. Becker K., Herold-Mende C., Park J.J., Lowe G., and Schirmer R.H. Human thioredoxin reductase is efficiently inhibited by (2,2′:6′,2″-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. J Med Chem 44 (2001) 2784-2792
10. Lo Y.C., Ko T.P., Su W.C., Su T.L., and Wang A.H.J. Terpyridine-platinum(II) complexes are effective inhibitors of mammalian topoisomerases and human thioredoxin reductase 1. J Inorg Biochem 103 (2009) 1082-1092
11. Arnesano F, Boccarelli A, Cornacchia D, Nushi F, Sasanelli R, Coluccia M, Natile G: Mechanistic insight into the inhibition of matrix metalloproteinases by platinum substrates. J Med Chem 2009, in press.
12. Ang W.H., Parker L.J., De Luca A., Juillerat-Jeanneret L., Morton C.J., Lo Bello M., Parker M.W., and Dyson P.J. Rational design of an organometallic glutathione transferase inhibitor. Angew Chem Int Ed Engl 48 (2009) 3854-3857
13. Hickey J.L., Ruhayel R.A., Barnard P.J., Baker M.V., Berners-Price S.J., and Filipovska A. Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J Am Chem Soc 130 (2008) 12570-12571
14. Montana A.M., and Batalla C. The rational design of anticancer platinum complexes: the importance of the structure-activity relationship. Curr Med Chem 16 (2009) 2235-2260
15. Che C.M., Sun R.W.Y., Yu W.Y., Ko C.B., Zhu N., and Sun H. Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity. DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. Chem Commun (Camb) (2003) 1718-1719. A substitution-inert gold(III) porphyrin complex (gold-1a) is found to be stable against GSH reduction.
16. Wang Y., He Q.Y., Sun R.W.Y., Che C.M., and Chiu J.F. Gold(III) porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res 65 (2005) 11553-11564
17. Wang Y., He Q.Y., Che C.M., Tsao S.W., Sun R.W.Y., and Chiu J.F. Modulation of gold(III) porphyrin 1a-induced apoptosis by mitogen-activated protein kinase signaling pathways. Biochem Pharmacol 75 (2008) 1282-1291
18. Lum C.T., Yang Z.F., Li H.Y., Sun R.W.Y., Fan S.T., Poon R.T.P., Lin M.C.M., Che C.M., and Kung H.F. Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma. Int J Cancer 118 (2006) 1527-1538
19. Tu S., Sun R.W.Y., Lin M.C.M., Cui J.T., Zou B., Gu Q., Kung H.F., Che C.M., and Wong B.C.Y. Gold (III) porphyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon cancer. Cancer 115 (2009) 4459-4469
20. Chow KHM, Sun RWY, Lam JBB, Li CKL, Xu A, MA DL, Abagyan R, Wang Y, Che CM: Anti-cancer complex gold(III) porphyrin 2a as a novel histone deacetylase inhibitor targeting Wnt/β-catenin pathway. Cancer Res 2009, in press. An in vivo study revealed that gold(III) porphyrin complex (gold-2a) is a potent anticancer agent and a novel histone deacetylase inhibitor.
21. Ma D.L., Che C.M., and Yan S.C. Platinum(II) complexes with dipyridophenazine ligands as human telomerase inhibitors and luminescent probes for G-quadruplex DNA. J Am Chem Soc 131 (2009) 1835-1846
22. Wu P., Ma D.L., Leung C.H., Yan C.H., Zhu N., Abagyan R., and Che C.M. Stabilization of G-Quadruplex DNA with platinum(II) Schiff-base complexes: luminescent probe and down regulation of c-myc oncogene expression. Chemistry 15 (2009) 13008-13021. A series of platinum(II) complexes, mimic organic stabilizers, were found to stabilize c-myc G-quadruplex DNA.
23. Anand R., Maksimoska J., Pagano N., Wong E.Y., Gimotty P.A., Diamond S.L., Meggers E., and Marmorstein R. Toward the development of a potent and selective organoruthenium mammalian sterile 20 kinase inhibitor. J Med Chem 52 (2009) 1602-1611. A series of organoruthenium complexes, mimic staurosporine, were found to be potent protein kinase inhibitors.
24. Atilla-Gokcumen G.E., Pagano N., Streu C., Maksimoska J., Filippakopoulos P., Knapp S., and Meggers E. Extremely tight binding of a ruthenium complex to glycogen synthase kinase 3. Chembiochem 9 (2008) 2933-2936
25. Maksimoska J., Feng L., Harms K., Yi C., Kissil J., Marmorstein R., and Meggers E. Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J Am Chem Soc 130 (2008) 15764-15765
26. Xie P., Streu C., Qin J., Bregman H., Pagano N., Meggers E., and Marmorstein R. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. Biochemistry 48 (2009) 5187-5198
27. Xie P., Williams D.S., Atilla-Gokcumen G.E., Milk L., Xiao M., Smalley K.S.M., Herlyn M., Meggers E., and Marmorstein R. Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem Biol 3 (2008) 305-316
28. 6] with potent anti-HIV activities. J Am Chem Soc 128 (2006) 4938-4939
29. Hughes B. 2008 FDA drug approvals. Nat Rev Drug Discov 8 (2009) 93-96